The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ALECTOR INC | COM | 014442107 | 9,053,652 | 980,894 | SH | SOLE | 980,894 | 0 | 0 | |||
| FIRST FINL BANCORP OH | COM | 320209109 | 4,205,746 | 173,576 | SH | SOLE | 173,576 | 0 | 0 | |||
| FOGHORN THERAPEUTICS INC | COM | 344174107 | 8,046,845 | 1,261,261 | SH | SOLE | 1,261,261 | 0 | 0 | |||
| 23ANDME HOLDING CO | CLASS A COM | 90138Q108 | 22,125,144 | 10,243,122 | SH | SOLE | 10,243,122 | 0 | 0 | |||
| NGM BIOPHARMACEUTICALS INC | COM | 62921N105 | 3,748,303 | 746,674 | SH | SOLE | 746,674 | 0 | 0 | |||
| ORIC PHARMACEUTICALS INC | COM | 68622P109 | 4,403,070 | 747,550 | SH | SOLE | 747,550 | 0 | 0 | |||
| PMV PHARMACEUTICALS INC | COM | 69353Y103 | 20,331,108 | 2,336,909 | SH | SOLE | 2,336,909 | 0 | 0 | |||
| RAPT THERAPEUTICS INC | COM | 75382E109 | 8,571,420 | 432,900 | SH | SOLE | 432,900 | 0 | 0 | |||
| SURROZEN INC | COM | 86889P109 | 467,244 | 802,963 | SH | SOLE | 802,963 | 0 | 0 | |||
| TENAYA THERAPEUTICS INC | COM | 87990A106 | 1,840,567 | 915,705 | SH | SOLE | 915,705 | 0 | 0 | |||
| ISHARES TR | MSCI INDIA ETF | 46429B598 | 24,089,991 | 577,144 | SH | SOLE | 577,144 | 0 | 0 | |||